JAN 2 7 2016

A BILL FOR AN ACT

RELATING TO DRUG OVERDOSE PREVENTION.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

- 1 SECTION 1. The legislature finds that unintentional drug
- 2 poisonings, commonly referred to as drug overdoses, are one of
- 3 the leading causes of injury-related mortality in Hawaii.
- 4 Opioid pain relievers, such as oxycodone or hydrocodone,
- 5 contributed to more than one-third of the seven hundred seventy-
- 6 eight known drug overdose deaths reported in Hawaii from 2010
- 7 through 2014.
- 8 Public health experts, including those at the Centers for
- 9 Disease Control and Prevention and the Substance Abuse and
- 10 Mental Health Services Administration, recommend increasing
- 11 access to naloxone hydrochloride, a pure opioid antagonist, to
- 12 prevent death due to opiate overdose. Currently, naloxone
- 13 hydrochloride is the only opiate antagonist medication approved
- 14 by the United States Food and Drug Administration to treat
- 15 opiate-induced central nervous system and respiratory
- 16 depression.



1	The purpose of this Act is to expand access to opioid
2	antagonists to reduce deaths by drug overdose in this State.
3	SECTION 2. The Hawaii Revised Statutes is amended by
4	adding a new chapter to be appropriately designated and to read
5	as follows:
6	"CHAPTER
7	OVERDOSE PREVENTION AND EMERGENCY RESPONSE
8	§ -1 Definitions. As used in this chapter, unless the
9	context otherwise requires:
10	"Harm reduction organization" means an organization that
11	provides services, including medical care, counseling, homeless
12	services, or addiction treatment, to individuals at risk of
13	experiencing an opiate-related drug overdose event or to the
14	friends and family members of an at-risk individual.
15	"Health care professional" includes a physician, physician
16	assistant under the authority and supervision of a physician,
17	and an advanced practice registered nurse who is authorized to
18	prescribe an opioid antagonist.
19	"Individual at risk of experiencing an opioid-related
20	overdose" includes an individual experiencing an opioid-related
21	overdose.

1	"Opioid antagonist" means any drug that binds to opioid	
2	receptors that is approved by the United States Food and Drug	
3	Administration for the treatment of opiate-induced central	
4	nervous system or respiratory depression.	
5	"Opioid-related drug overdose" includes:	
6	(1) Extreme physical illness, decreased level of	
7	consciousness, respiratory depression, coma, or death	
8	resulting from the consumption or use of:	
9	(A) An opioid; or	
10	(B) A substance combined with an opioid; or	
11	(2) A condition that a layperson would reasonably believe	
12	to be an opioid-related drug overdose that requires	
13	medical assistance.	
14	"Person" shall not include a harm reduction organization.	
15	"Standing order" means a prescription order written by a	
16	physician or physician assistant that is not specific to and	
17	does not identify a particular patient.	
18	§ -2 Health care professional; prescribing, dispensing,	
19	or administering an opioid antagonist. Notwithstanding any	
20	other law to the contrary, a health care professional may	
21	directly or in accordance with a standing order:	

1	(1)	Prescribe, dispense, or administer an opioid
2		antagonist to an individual at risk of experiencing an
3		opioid-related overdose;
4	(2)	Dispense an opioid antagonist to a person in a
5		position to assist an individual at risk of
6		experiencing an opioid-related overdose; and
7	(3)	Dispense an opioid antagonist to a harm reduction
8		organization.
9	§ -	-3 Pharmacist; dispensing an opioid antagonist.
10	Notwithsta	anding any other law to the contrary, and pursuant to a
11	standing (order and rules adopted by the board of pharmacy
12	pursuant †	to chapter 91, a pharmacist may dispense an opioid
13	antagonis	t to:
14	(1)	A individual at risk of experiencing an opioid-related
15		overdose;
16	(2)	A person in a position to assist an individual at risk
17		of experiencing an opioid-related overdose; or
18	(3)	A harm reduction organization,
19	that does	not hold a prescription for an opioid antagonist.
20	§	-4 Harm reduction organization; dispensing or
21	administe:	ring an opioid antagonist. Notwithstanding any other

- 1 law to the contrary, a harm reduction organization that has
- 2 received an opioid antagonist from a health care professional or
- 3 pharmacist, pursuant to this chapter, may:
- 4 (1) Administer an opioid antagonist to an individual at
- 5 risk of experiencing an opioid-related overdose; or
- 6 (2) Dispense an opioid antagonist to a person in a
- 7 position to assist an individual at risk of
- 8 experiencing an opioid-related overdose;
- 9 provided that the administering or dispensing is without charge
- 10 or compensation.
- 11 § -5 Person in a position to assist an individual at
- 12 risk of experiencing an opioid-related overdose; administering
- 13 an opioid antagonist. Notwithstanding any other law to the
- 14 contrary, a person in a position to assist an individual at risk
- 15 of experiencing an opioid-related overdose, who has received an
- 16 opioid antagonist from a health care professional, pharmacist,
- 17 or a harm reduction organization, pursuant to this chapter, may
- 18 administer an opioid antagonist to an individual at risk of
- 19 experiencing an opioid-related overdose; provided that the
- 20 administering or dispensing is without charge or compensation.

- 1 § -6 Emergency related personnel; administering an
- 2 opioid antagonist. Notwithstanding any other law to the
- 3 contrary, any emergency medical services personnel, law
- 4 enforcement officer, or firefighter may administer an opioid
- 5 antagonist to an individual at risk of experiencing an opioid-
- 6 related overdose.
- 7 § -7 Legitimate medical purpose. The prescribing,
- 8 dispensing, or administering of an opioid antagonist pursuant to
- 9 this chapter shall be regarded as being for a legitimate medical
- 10 purpose in the usual course of professional practice.
- 11 § -8 Immunity. Any health care professional,
- 12 pharmacist, harm reduction organization, person in a position to
- 13 assist an individual at risk of experiencing an opioid-related
- 14 overdose, emergency medical services personnel, law enforcement
- 15 officer, or firefighter, acting in good faith and with
- 16 reasonable care, who prescribes, dispenses, or administers an
- 17 opioid antagonist pursuant to this chapter shall not be subject
- 18 to:
- 19 (1) Criminal prosecution;
- 20 (2) Sanction under any professional licensing statute; or
- 21 (3) Civil liability,

- 1 for the prescribing, dispensing, or administering of an opioid
- 2 antagonist and any outcome that results from the administration
- 3 of the opioid antagonist.
- 4 § -9 Medicaid coverage. The department of human
- 5 services shall ensure that naloxone hydrochloride for outpatient
- 6 use is covered by the medicaid prescription drug program on the
- 7 same basis as other covered drugs.
- 8 § -10 Authorization to store an opioid antagonist.
- 9 Notwithstanding any other law to the contrary,
- 10 (1) A harm reduction organization that has received an
- opioid antagonist from a health care professional or
- pharmacist, pursuant to this chapter; or
- 13 (2) A person in a position to assist an individual at risk
- of experiencing an opioid-related overdose that has
- 15 received an opioid antagonist from a health care
- 16 professional, pharmacist, or harm reduction
- organization, pursuant to this chapter,
- 18 may possess and store an opioid antagonist without being subject.
- 19 to parts I and VI of chapter 328.
- 20 § -11 Rules. The department of health shall adopt rules
- 21 in accordance with chapter 91 to implement this chapter.

1	§ -12 Unintentional drug overdose; reporting. The
2	department of health shall provide to the legislature an annual
3	report no later than twenty days prior to the convening of each
4	regular session. The report shall ascertain, document, and
5	publish the number of, trends in, patterns in, and risk factors
6	related to unintentional opioid related drug overdose fatalities
7	occurring each year within the State. The report shall provide
8	information on interventions that would be effective in reducing
9	the rate of fatal or nonfatal drug overdose."
10	SECTION 3. This Act does not affect rights and duties that
11	matured, penalties that were incurred, and proceedings that were
12	begun before its effective date.
13	SECTION 4. This Act shall take effect upon its approval.
14	
	INTRODUCED BY: ON S.C. Kirk-Again

SB LRB 16-0813.doc

Report Title:

Opioid Antagonist; Naloxone Hydrochloride; Opioid Overdose; Prevention; Emergency Response; Medical Immunity

Description:

Provides immunity for individuals and harm reduction organizations who prescribe, possess, or administer an opioid antagonist such as naloxone hydrochloride to prevent opioid-related drug overdoses. Authorizes emergency personnel and first responders to administer opioid antagonists. Requires medicaid coverage for opioid antagonists. Exempts individuals and harm reduction organizations from licensure and permitting requirements for storing and distributing opioid antagonists. Allows pharmacists, in accordance with standing orders and protocols, to dispense opioid antagonists to persons and harm reduction organizations without a prescription.

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.

SB LRB 16-0813.doc